Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Becton, Dickinson and Company BDXA NYSE

NYSE • Healthcare • Medical - Instruments & Supplies • USD

SharesGrow Score
68/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Becton, Dickinson and Company (BDXA) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $59.24. It has a SharesGrow Score of 66/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Financials: revenue is $21.8B, +5%/yr average growth. Net income is $1.7B, growing at -1.1%/yr. Net profit margin is 7.7% (thin). Gross margin is 45.4% (+0.5 pp trend).

Balance sheet: total debt is $19.2B against $25.4B equity (Debt-to-Equity (D/E) ratio 0.76, moderate). Current ratio is 1.11 (adequate). Debt-to-assets is 34.7%. Total assets: $55.3B.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 40/100 (Partial), Past 100/100 (Pass), Health 50/100 (Partial), Moat 73/100 (Pass), Future ?/100 (Fail), Income 45/100 (Partial).

BDXA SharesGrow Score Overview

68/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 40/100
Financials — average growth
PAST 100/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 73/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 45/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BDXA

✓
VALUE Pass
100/100
BDXA trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
40/100
BDXA: +5%/yr revenue is, -1.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✓
PAST Pass
100/100
BDXA: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
50/100
Balance sheet BDXA: Debt-to-Equity (D/E) ratio 0.76 (moderate), Current ratio is 1.11 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
MOAT Pass
73/100
BDXA: Gross margin is 45.4% (+0.5 pp trend), $56B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 73/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
~
INCOME Partial
45/100
BDXA: Net profit margin is 7.7%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range49.07-64.12
Volume6.15M
Market Cap$55.91B
Beta (1Y)0.00
Share Statistics
EPS (TTM)5.84
Shares Outstanding$286.61M
IPO Date2017-05-11
Financial Highlights & Ratios
Revenue (TTM)$21.84B
Gross Profit$9.92B
EBITDA$4.96B
Net Income$1.68B
Operating Income$2.58B
Total Cash$859M
Total Debt$19.18B
Net Debt$18.33B
Total Assets$55.33B
Price / Earnings (P/E)10.1
Price / Sales (P/S)2.56
Analyst Forecast
Company Info
ExchangeNYSE
CurrencyUSD

Price Chart

Track all markets on TradingView
BDXA
Becton, Dickinson and Company  ·  NYSE
Healthcare • Medical - Instruments & Supplies
49.07 52WK RANGE 64.12

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message